IP Library Granted Patent US 8,772,456
Granted Patent B2
US 8,772,456 · App. 13/934,828 · Granted Jul 8, 2014

Fibrous protein fusion and use thereof in the formation of advanced organic/inorganic composite materials

Inventors: David L. Kaplan (Concord, MA); Jia Huang (Malden, MA); Cheryl Wong Po Foo (Santa Clara, CA); Rajesh Naik (Dayton, OH); Anne George (Chicago, IL)
Assignee: Trustees of Tufts College
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,772,456
App. No.
13/934,828
Granted
Jul 8, 2014
Kind
B2
Abstract

The claimed invention provides a fusion polypeptide comprising a fibrous protein domain and a mineralization domain. The fusion is used to form an organic-inorganic composite. These organic-inorganic composites can be constructed from the nano- to the macro-scale depending on the size of the fibrous protein fusion domain used. In one embodiment, the composites can also be loaded with other compounds (e.g., dyes, drugs, enzymes) depending on the goal for the materials, to further enhance function. This can be achieved during assembly of the material or during the mineralization step in materials formation.

Claims (18)

1. An organic-inorganic composite material comprising: (i) a fusion polypeptide comprising a fibrous protein domain comprising the amino acid sequence as set forth in SEQ ID NO: 1 or 3 and a mineralizing domain, wherein the mineralizing domain is capable of inducing mineralization, and is obtained from dentin matrix protein 1 (DMP1), bone sialoprotein (BSP), silaffin-1 (Sil1) protein, or functional fragments thereof; and (ii) an inorganic material.

2. The organic-inorganic composite material of claim 1 , wherein the fibrous protein domain is obtained from silk, collagens, coiled-coiled leucine zipper proteins, elastins, keratins, actins, or tubulins.

3. The organic-inorganic composite material of claim 1 , wherein the fibrous protein domain comprises an amino acid sequence from the silk protein Spidroin 1.

4. The organic-inorganic composite material of claim 1 , wherein the fibrous protein domain comprises an amino acid sequence as set forth in SEQ ID NO: 4 or SEQ ID NO: 5.

5. The organic-inorganic composite material of claim 1 , wherein the fusion polypeptide is crystallized.

6. The organic-inorganic composite material of claim 1 , wherein the mineralizing domain induces the formation of hydroxyapatite, silica, cadmium sulfide or magnetite.

7. The organic-inorganic composite material of claim 1 , wherein the mineralization domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 6, 8, and 17-21.

8. The organic-inorganic composite material of claim 7 , wherein the mineralization domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 7, 22, and 23.

9. The organic-inorganic composite material of claim 1 , wherein the fusion polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 9-12, 24, and 25.

10. The organic-inorganic composite material of claim 1 , wherein the inorganic material is hydroxyapatite or silica.

11. The organic-inorganic composite material of claim 1 , wherein the organic-inorganic composite material further comprises an active agent.

12. The organic-inorganic composite material of claim 11 , wherein the agent is selected from the group consisting of naturally derived or genetically engineered proteins, polysaccharides, glycoproteins, lipoproteins, peptides, nucleic acids, PNAs, aptamers, antibodies, small molecules, and cells.

13. The organic-inorganic composite material of claim 11 , wherein the agent is a therapeutic agent, a cell attachment mediator, a hormone, a chemoattractant, or a growth factor.

14. The organic-inorganic composite material of claim 13 , wherein the cell attachment mediator comprises an integrin binding amino acid sequence.

15. The organic-inorganic composite material of claim 13 , wherein the therapeutic agent is selected from the group consisting of anti-infectives; chemotherapeutic agents; anti-rejection agents; analgesics and analgesic combinations; and anti-inflammatory agents.

16. The organic-inorganic composite material of claim 13 , wherein the growth factor is selected from the group consisting of bone morphogenic proteins, bone morphogenaic-like proteins, epidermal growth factors, fibroblast growth factors, platelet derived growth factor (PDGF), insulin like growth factors, transforming growth factors, and vascular endothelial growth factor (VEGF).

17. The organic-inorganic composite material of claim 1 , wherein the organic-inorganic composite material is in a form selected from a fiber, a film, a sponge, a gel, a foam, and a micropatterned foam.

18. A tissue engineered scaffold comprising an organic-inorganic composite material of claim 1 .

Assignments (2)
CONFIRMATORY LICENSE Recorded Jun 22, 2016
From: TUFTS UNIVERSITY BOSTON
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 039113/0478 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2013
From: THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE AIR FORCE
To: TRUSTEES OF TUFTS COLLEGE
Reel/Frame 031781/0783 →
Continuity (5)
Continuation 13347801 · Jan 11, 2012
Continuation 13097538 · Apr 29, 2011
Continuation 11794934
Provisional Application 60644264 · Jan 14, 2005
Related Publication 20140142048A1 · May 22, 2014